Compare ClearPoint Neuro Inc (CLPT) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Xpeng Inc - ADR — how do they compare? ClearPoint Neuro Inc trades at $16.07 (market cap $478.63M), while Xpeng Inc - ADR trades at $13.75 (market cap $12.77B). The key difference: Xpeng Inc - ADR is far larger — about 26.7× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| CLPT | XPEV | |
|---|---|---|
Market Cap | $478.63M | $12.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $28.07 |
52-Week Low | $8.66 | $12.09 |
Enterprise Value | $506.63M | $14.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
XPeng (XPEV) trades at $12.95, down 0.61% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 deliveries of 103,295 vehicles, beating guidance, but continues to post net losses with a -3.06% margin. Revenue grew to $76.72B in 2025, though cash flow from operations was negative $2.01B in 2024. Analyst sentiment is mixed with 64.7% buy ratings.
The outlook hinges on XPeng's ability to achieve profitability amid expansion. Opportunities include new model launches and international growth, but risks persist from intense EV competition and ongoing cash burn. The stock's valuation at P/S of 1.14 may attract value investors if margins improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
